{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:30:12Z","timestamp":1761921012414,"version":"3.44.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T00:00:00Z","timestamp":1649289600000},"content-version":"vor","delay-in-days":96,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010032","name":"Health and Family Planning Commission of Sichuan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010032","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Commission of Health and Family Planning","doi-asserted-by":"publisher","award":["201640193"],"award-info":[{"award-number":["201640193"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Therapeutic Research"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.curtheres.2022.100671","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T12:56:06Z","timestamp":1649768166000},"page":"100671","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Associations Between Cessation of Second-Line Therapies and Relapse Rates of Childhood Refractory Minimal-Change Nephrotic Syndrome: A Single-Center, Retrospective Chart Review"],"prefix":"10.1016","volume":"96","author":[{"given":"Jing","family":"Jin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6633-989X","authenticated-orcid":false,"given":"Yufeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaju","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiajia","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9384","key":"10.1016\/j.curtheres.2022.100671_bib0001","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(03)14184-0","article-title":"Nephrotic syndrome in childhood","volume":"362","author":"Eddy","year":"2003","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.curtheres.2022.100671_bib0002","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/archdischild-2015-308924","article-title":"Steroid-sensitive nephrotic syndrome: an evidence-based update of immunosuppressive treatment in children","volume":"101","author":"Larkins","year":"2016","journal-title":"Arch Dis Child"},{"issue":"8","key":"10.1016\/j.curtheres.2022.100671_bib0003","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1007\/s00467-009-1138-5","article-title":"Long-term outcome of idiopathic steroid-resistant nephrotic syndrome: a multicenter study","volume":"24","author":"Mekahli","year":"2009","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"10.1016\/j.curtheres.2022.100671_bib0004","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1046\/j.1365-2796.2003.01207.x","article-title":"Causes and consequences of proteinuria: the kidney filtration barrier and progressive renal failure","volume":"254","author":"Tryggvason","year":"2003","journal-title":"J Intern Med"},{"issue":"6","key":"10.1016\/j.curtheres.2022.100671_bib0005","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00467-010-1717-5","article-title":"New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome","volume":"26","author":"van Husen","year":"2011","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"10.1016\/j.curtheres.2022.100671_bib0006","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000357355","article-title":"Second-line immunosuppressive treatment of childhood nephrotic syndrome: a single-center experience","volume":"4","author":"Kim","year":"2014","journal-title":"Nephron Extra"},{"issue":"5","key":"10.1016\/j.curtheres.2022.100671_bib0007","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1053\/j.ajkd.2007.02.270","article-title":"Long-term outcome after cyclophosphamide treatment in children with steroid-dependent and frequently relapsing minimal change nephrotic syndrome","volume":"49","author":"Kyrieleis","year":"2007","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"10.1016\/j.curtheres.2022.100671_bib0008","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s00467-020-04519-1","article-title":"IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome","volume":"35","author":"Trautmann","year":"2020","journal-title":"Pediatr Nephrol"},{"issue":"12","key":"10.1016\/j.curtheres.2022.100671_bib0009","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S2352-4642(18)30283-9","article-title":"Management of steroid-resistant nephrotic syndrome in children and adolescents","volume":"2","author":"Tullus","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"issue":"1","key":"10.1016\/j.curtheres.2022.100671_bib0010","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s12519-015-0062-y","article-title":"Tacrolimus for children with refractory nephrotic syndrome: a one-year prospective, multicenter, and open-label study of Tacrobell\u00ae, a generic formula","volume":"12","author":"Yang","year":"2016","journal-title":"World J Pediatr"},{"issue":"6","key":"10.1016\/j.curtheres.2022.100671_bib0011","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2215\/CJN.00550206","article-title":"Mycophenolate mofetil in children with frequently relapsing nephrotic syndrome: a report from the Southwest Pediatric Nephrology Study Group","volume":"1","author":"Hogg","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.curtheres.2022.100671_bib0012","doi-asserted-by":"crossref","first-page":"13083","DOI":"10.1038\/s41598-021-92573-6","article-title":"The immune cell landscape of peripheral blood mononuclear cells from PNS patients","volume":"11","author":"Ye","year":"2021","journal-title":"Sci Rep"},{"issue":"29","key":"10.1016\/j.curtheres.2022.100671_bib0013","doi-asserted-by":"crossref","first-page":"e11598","DOI":"10.1097\/MD.0000000000011598","article-title":"Adjuvant treatment with Yupingfeng formula for primary nephrotic syndrome in children: a PRISMA systematic review and meta-analysis of randomized controlled trials","volume":"97","author":"Shi","year":"2018","journal-title":"Med (Baltim)"},{"issue":"2","key":"10.1016\/j.curtheres.2022.100671_bib0014","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.19082\/3728","article-title":"Immunoglobulin G and M levels in childhood nephrotic syndrome: two centers Egyptian study","volume":"9","author":"El Mashad","year":"2017","journal-title":"Electron Physician"},{"key":"10.1016\/j.curtheres.2022.100671_bib0015","first-page":"139","article-title":"KDIGO clinical practice guideline for glomerulonephritis","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"issue":"2","key":"10.1016\/j.curtheres.2022.100671_bib0016","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000085357","article-title":"Changes of lymphocyte populations in pediatric steroid-sensitive nephrotic syndrome are more pronounced in remission than in relapse","volume":"25","author":"Kemper","year":"2005","journal-title":"Am J Nephrol"},{"issue":"02","key":"10.1016\/j.curtheres.2022.100671_bib0017","first-page":"111","article-title":"Pathological patterns of renal biopsy with immunofluorescence relate to the therapeutic effects of corticosteroid in childhood nephrotic syndrome","volume":"35","author":"Wen-jie","year":"2017","journal-title":"Clin Pediatr"},{"issue":"3","key":"10.1016\/j.curtheres.2022.100671_bib0018","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00467-012-2310-x","article-title":"Improving Global Outcomes. Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO","volume":"28","author":"Lombel","year":"2013","journal-title":"Pediatr Nephrol"},{"issue":"8-9","key":"10.1016\/j.curtheres.2022.100671_bib0019","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1007\/PL00013435","article-title":"Unfavorable response to cyclophosphamide in steroid-dependent nephrotic syndrome","volume":"14","author":"Kemper","year":"2000","journal-title":"Pediatr Nephrol"},{"issue":"11","key":"10.1016\/j.curtheres.2022.100671_bib0020","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1093\/ndt\/17.11.2011","article-title":"Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome","volume":"17","author":"Day","year":"2002","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.curtheres.2022.100671_bib0021","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1080\/20469047.2017.1374003","article-title":"Nephrotic syndrome in infants and children: pathophysiology and management","volume":"37","author":"Downie","year":"2017","journal-title":"Paediatr Int Child Health"},{"key":"10.1016\/j.curtheres.2022.100671_bib0022","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaut.2017.10.006","article-title":"NEPHRUTIX: A randomized, double-blind, placebo vs rituximab-controlled trial assessing T-cell subset changes in Minimal Change nephrotic syndrome","volume":"88","author":"Boumediene","year":"2018","journal-title":"J Autoimmun"},{"issue":"10","key":"10.1016\/j.curtheres.2022.100671_bib0023","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/ki.2012.238","article-title":"Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome","volume":"82","author":"Gulati","year":"2012","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.curtheres.2022.100671_bib0024","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.kint.2017.01.019","article-title":"Mycophenolate mofetil is inferior to tacrolimus in sustaining remission in children with idiopathic steroid-resistant nephrotic syndrome","volume":"92","author":"Sinha","year":"2017","journal-title":"Kidney Int"},{"issue":"11","key":"10.1016\/j.curtheres.2022.100671_bib0025","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1007\/s00467-015-3133-3","article-title":"Clinical efficacy and pharmacokinetics of tacrolimus in children with steroid-resistant nephrotic syndrome","volume":"30","author":"Jahan","year":"2015","journal-title":"Pediatr Nephrol"}],"container-title":["Current Therapeutic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X22000108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X22000108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:59:06Z","timestamp":1757897946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011393X22000108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":25,"alternative-id":["S0011393X22000108"],"URL":"https:\/\/doi.org\/10.1016\/j.curtheres.2022.100671","relation":{},"ISSN":["0011-393X"],"issn-type":[{"type":"print","value":"0011-393X"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Associations Between Cessation of Second-Line Therapies and Relapse Rates of Childhood Refractory Minimal-Change Nephrotic Syndrome: A Single-Center, Retrospective Chart Review","name":"articletitle","label":"Article Title"},{"value":"Current Therapeutic Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.curtheres.2022.100671","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100671"}}